KEY FEATURES 

Therapeutic Class: Melanocortin receptor agonist peptide
Primary Use: Treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women

Mechanism of Action: Activates MC3 and MC4 receptors in the central nervous system → enhances sexual desire pathways

Clinical Benefits:

Improves sexual desire and reduces distress associated with HSDD

First FDA‑approved on‑demand therapy for female sexual dysfunction

TECHNICAL SPECIFICATIONS:

Molecular Type: Synthetic cyclic heptapeptide lactam analogue of α‑MSH
Molecular Formula: C₅₀H₆₈N₁₄O₁₀
Molecular Weight: ~1025.2 g/mol
Dosage Form: Prefilled single‑use autoinjector
Strength: 1.75 mg per injection
Administration Route: Subcutaneous (abdomen or thigh)

Pharmacokinetics:

Bioavailability: ~100% (SC injection)

Half‑life: ~2.7 hours
Excretion: ~65% urine, ~23% feces
Storange & Handling:

Store refrigerated (2–8 °C)

Protect from light; do not freeze

Safety Profile:

Common side effects: nausea, flushing, headache, injection site reactions
Serious risks: transient hypertension, skin hyperpigmentation
Contraindications: uncontrolled hypertension, cardiovascular disease, pregnancy

AVAILABLE CONFIGURATIONS 

Format & Delivery:

Prefilled single‑dose autoinjectors (1.75 mg)

Bulk API (for research or compounding supply)

Packaging & Labeling:

Retail‑ready cartons with 4 autoinjectors per box

Bulk peptide shipments for B2B supply

Private labeling / white‑label options for distributors